APA (7th ed.) Citation

Bilgin, B., Sendur, M. A. N., Yucel, S., Celik, E., Ozyukseler, D. T., Ayhan, M., . . . Hizal, M. (2021). Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: A Turk Oncology Group (TOG) study. Journal of Cancer Research & Clinical Oncology, 147(7), 2145. https://doi.org/10.1007/s00432-020-03501-6

Chicago Style (17th ed.) Citation

Bilgin, Burak, et al. "Real-life Comparison of the Afatinib and First-generation Tyrosine Kinase Inhibitors in Nonsmall Cell Lung Cancer Harboring EGFR Exon 19 Deletion: A Turk Oncology Group (TOG) Study." Journal of Cancer Research & Clinical Oncology 147, no. 7 (2021): 2145. https://doi.org/10.1007/s00432-020-03501-6.

MLA (9th ed.) Citation

Bilgin, Burak, et al. "Real-life Comparison of the Afatinib and First-generation Tyrosine Kinase Inhibitors in Nonsmall Cell Lung Cancer Harboring EGFR Exon 19 Deletion: A Turk Oncology Group (TOG) Study." Journal of Cancer Research & Clinical Oncology, vol. 147, no. 7, 2021, p. 2145, https://doi.org/10.1007/s00432-020-03501-6.